Skip to main content
Top
Published in: Drugs & Aging 8/2012

01-08-2012 | Original Research Article

Inappropriate Prescribing of Proton Pump Inhibitors in Older Patients

Effects of an Educational Strategy

Authors: Hanifat Hamzat, Hao Sun, Joanna C. Ford, Joan MacLeod, Roy L. Soiza, Professor Arduino A. Mangoni

Published in: Drugs & Aging | Issue 8/2012

Login to get access

Abstract

Background

An increasing number of older patients are prescribed proton pump inhibitors (PPIs). However, the extent of inappropriate PPI prescribing in this group is largely unknown.

Objective

We sought to identify clinical and demographic factors associated with inappropriate PPI prescribing in older patients and to assess the effects of a targeted educational strategy in a controlled hospital environment.

Methods

Clinical and demographic characteristics and full medication exposure on admission were recorded in 440 consecutive older patients (mean ± SD age 84 ± 7 years) admitted to a teaching hospital between 1 February 2011 and 30 June 2011. A 4-week educational strategy to reduce inappropriate PPI prescribing during hospital stay, either by stopping or reducing PPI doses, was conducted within the study period. The main outcome measures of the study were the incidence of inappropriate PPI prescribing and the effects of interventions to reduce it.

Results

On admission, PPIs were established therapy in 164 patients (37%). This was considered inappropriate in 100 patients (61%). Lower Charlson Comorbidity Index score (odds ratio [OR] 0.76; 95% CI 0.57, 0.94; p = 0.006) and history of dementia (OR 1.65; 95% CI 1.28, 1.83; p = 0.005) were independently associated with inappropriate PPI prescribing. Interventions to reduce inappropriate PPI prescribing occurred more frequently during and after the education phase (frequency of interventions in patients with inappropriate PPI prescribing: pre-education phase 9%, during education phase 43%, and post-education phase 46%, p=0.006). Prescribing interventions were not associated with acid rebound symptoms.

Conclusions

Inappropriate PPI prescribing in older patients is frequent and independently associated with co-morbidities and dementia. A targeted inhospital educational strategy can significantly and safely reduce inappropriate PPI prescribing in the short term.
Literature
1.
go back to reference Shi S, Klotz U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol 2008; 64 (10): 935–51.PubMedCrossRef Shi S, Klotz U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol 2008; 64 (10): 935–51.PubMedCrossRef
2.
go back to reference Hollingworth S, Duncan EL, Martin JH. Marked increase in proton pump inhibitors use in Australia. Pharmacoepidemiol Drug Saf 2010; 19 (10): 1019–24.PubMedCrossRef Hollingworth S, Duncan EL, Martin JH. Marked increase in proton pump inhibitors use in Australia. Pharmacoepidemiol Drug Saf 2010; 19 (10): 1019–24.PubMedCrossRef
3.
go back to reference Chen TJ, Chou LF, Hwang SJ. Trends in prescribing proton pump inhibitors in Taiwan: 1. Int J Clin Pharmacol Ther 2003; 41 (5): 207–12.PubMed Chen TJ, Chou LF, Hwang SJ. Trends in prescribing proton pump inhibitors in Taiwan: 1. Int J Clin Pharmacol Ther 2003; 41 (5): 207–12.PubMed
4.
go back to reference Martin RM, Lim AG, Kerry SM, et al. Trends in prescribing H2-receptor antagonists and proton pump inhibitors in primary care. Aliment Pharmacol Ther 1998; 12 (8): 797–805.PubMedCrossRef Martin RM, Lim AG, Kerry SM, et al. Trends in prescribing H2-receptor antagonists and proton pump inhibitors in primary care. Aliment Pharmacol Ther 1998; 12 (8): 797–805.PubMedCrossRef
5.
go back to reference Bashford JN, Norwood J, Chapman SR. Why are patients prescribed proton pump inhibitors? Retrospective analysis of link between morbidity and prescribing in the General Practice Research Database. BMJ 1998; 317 (7156): 452–6.PubMedCrossRef Bashford JN, Norwood J, Chapman SR. Why are patients prescribed proton pump inhibitors? Retrospective analysis of link between morbidity and prescribing in the General Practice Research Database. BMJ 1998; 317 (7156): 452–6.PubMedCrossRef
6.
7.
go back to reference Sheen E, Triadafilopoulos G. Adverse effects of long-term proton pump inhibitor therapy. Dig Dis Sci 2011; 56 (4): 931–50.PubMedCrossRef Sheen E, Triadafilopoulos G. Adverse effects of long-term proton pump inhibitor therapy. Dig Dis Sci 2011; 56 (4): 931–50.PubMedCrossRef
8.
go back to reference McCarthy DM. Adverse effects of proton pump inhibitor drugs: clues and conclusions. Curr Opin Gastroenterol 2010; 26 (6): 624–31.PubMedCrossRef McCarthy DM. Adverse effects of proton pump inhibitor drugs: clues and conclusions. Curr Opin Gastroenterol 2010; 26 (6): 624–31.PubMedCrossRef
9.
go back to reference Ali T, Roberts DN, Tierney WM. Long-term safety concerns with proton pump inhibitors. Am J Med 2009; 122 (10): 896–903.PubMedCrossRef Ali T, Roberts DN, Tierney WM. Long-term safety concerns with proton pump inhibitors. Am J Med 2009; 122 (10): 896–903.PubMedCrossRef
10.
go back to reference Jackson SH, Mangoni AA, Batty GM. Optimization of drug prescribing. Br J Clin Pharmacol 2004; 57 (3): 231–6.PubMedCrossRef Jackson SH, Mangoni AA, Batty GM. Optimization of drug prescribing. Br J Clin Pharmacol 2004; 57 (3): 231–6.PubMedCrossRef
11.
go back to reference Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol 2004; 57 (1): 6–14.PubMedCrossRef Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol 2004; 57 (1): 6–14.PubMedCrossRef
12.
go back to reference Reimer C, Sondergaard B, Hilsted L, et al. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology 2009; 137 (1): 80–7, 87.PubMedCrossRef Reimer C, Sondergaard B, Hilsted L, et al. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology 2009; 137 (1): 80–7, 87.PubMedCrossRef
13.
go back to reference Niklasson A, Lindstrom L, Simren M, et al. Dyspeptic symptom development after discontinuation of a proton pump inhibitor: a double-blind placebo-controlled trial. Am J Gastroenterol 2010; 105 (7): 1531–7.PubMedCrossRef Niklasson A, Lindstrom L, Simren M, et al. Dyspeptic symptom development after discontinuation of a proton pump inhibitor: a double-blind placebo-controlled trial. Am J Gastroenterol 2010; 105 (7): 1531–7.PubMedCrossRef
14.
go back to reference Jones MI, Greenfield SM, Jowett S, et al. Proton pump inhibitors: a study of GPs’ prescribing. Fam Pract 2001; 18 (3): 333–8.PubMedCrossRef Jones MI, Greenfield SM, Jowett S, et al. Proton pump inhibitors: a study of GPs’ prescribing. Fam Pract 2001; 18 (3): 333–8.PubMedCrossRef
15.
go back to reference de GV, Beckerman H, Lankhorst GJ, et al. How to measure comorbidity: a critical review of available methods. J Clin Epidemiol 2003; 56 (3): 221–9.PubMedCrossRef de GV, Beckerman H, Lankhorst GJ, et al. How to measure comorbidity: a critical review of available methods. J Clin Epidemiol 2003; 56 (3): 221–9.PubMedCrossRef
16.
go back to reference Hall WH, Ramachandran R, Narayan S, et al. An electronic application for rapidly calculating Charlson comorbidity score. BMC Cancer 2004; 4: 94.PubMedCrossRef Hall WH, Ramachandran R, Narayan S, et al. An electronic application for rapidly calculating Charlson comorbidity score. BMC Cancer 2004; 4: 94.PubMedCrossRef
17.
go back to reference Maconi G, Manes G, Porro GB. Role of symptoms in diagnosis and outcome of gastric cancer. World J Gastroenterol 2008; 14 (8): 1149–55.PubMedCrossRef Maconi G, Manes G, Porro GB. Role of symptoms in diagnosis and outcome of gastric cancer. World J Gastroenterol 2008; 14 (8): 1149–55.PubMedCrossRef
18.
go back to reference Proton pump inhibitors. In: British Medical Association and the Royal Pharmaceutical Society. British national formulary. 61st ed. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 2011. Proton pump inhibitors. In: British Medical Association and the Royal Pharmaceutical Society. British national formulary. 61st ed. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 2011.
19.
go back to reference National Institute of Clinical Excellence (NICE). Guidance on the use of proton pump inhibitors in the treatment of dyspepsia. NICE Technology Appraisal Guidance No. 7. London: NICE, 2000. National Institute of Clinical Excellence (NICE). Guidance on the use of proton pump inhibitors in the treatment of dyspepsia. NICE Technology Appraisal Guidance No. 7. London: NICE, 2000.
20.
go back to reference Pasina L, Nobili A, Tettamanti M, et al. Prevalence and appropriateness of drug prescriptions for peptic ulcer and gastro-esophageal reflux disease in a cohort of hospitalized elderly. Eur J Intern Med 2011; 22 (2): 205–10.PubMedCrossRef Pasina L, Nobili A, Tettamanti M, et al. Prevalence and appropriateness of drug prescriptions for peptic ulcer and gastro-esophageal reflux disease in a cohort of hospitalized elderly. Eur J Intern Med 2011; 22 (2): 205–10.PubMedCrossRef
21.
go back to reference Shrestha K, Hughes JD, Lee YP, et al. The prevalence of co-administration of clopidogrel and proton pump inhibitors. Qual Prim Care 2011; 19 (1): 35–42.PubMed Shrestha K, Hughes JD, Lee YP, et al. The prevalence of co-administration of clopidogrel and proton pump inhibitors. Qual Prim Care 2011; 19 (1): 35–42.PubMed
22.
go back to reference van Dijk KN, ter Huurne K, de Vries CS, et al. Prescribing of gastroprotective drugs among elderly NSAID users in the Netherlands. Pharm World Sci 2002; 24 (3): 100–3.PubMedCrossRef van Dijk KN, ter Huurne K, de Vries CS, et al. Prescribing of gastroprotective drugs among elderly NSAID users in the Netherlands. Pharm World Sci 2002; 24 (3): 100–3.PubMedCrossRef
23.
go back to reference Ntaios G, Chatzinikolaou A, Kaiafa G, et al. Evaluation of use of proton pump inhibitors in Greece. Eur J Intern Med 2009; 20 (2): 171–3.PubMedCrossRef Ntaios G, Chatzinikolaou A, Kaiafa G, et al. Evaluation of use of proton pump inhibitors in Greece. Eur J Intern Med 2009; 20 (2): 171–3.PubMedCrossRef
24.
go back to reference Gillen D, McColl KE. Does concern about missing malignancy justify endoscopy in uncomplicated dyspepsia in patients aged less than 55? Am J Gastroenterol 1999; 94 (1): 75–9.PubMedCrossRef Gillen D, McColl KE. Does concern about missing malignancy justify endoscopy in uncomplicated dyspepsia in patients aged less than 55? Am J Gastroenterol 1999; 94 (1): 75–9.PubMedCrossRef
25.
go back to reference Wayman J, Hayes N, Raimes SA, et al. Prescription of proton pump inhibitors before endoscopy: a potential cause of missed diagnosis of early gastric cancers. Arch Fam Med 2000; 9 (4): 385–8.PubMedCrossRef Wayman J, Hayes N, Raimes SA, et al. Prescription of proton pump inhibitors before endoscopy: a potential cause of missed diagnosis of early gastric cancers. Arch Fam Med 2000; 9 (4): 385–8.PubMedCrossRef
26.
go back to reference Naunton M, Peterson GM, Bleasel MD. Overuse of proton pump inhibitors. J Clin Pharm Ther 2000; 25 (5): 333–40.PubMedCrossRef Naunton M, Peterson GM, Bleasel MD. Overuse of proton pump inhibitors. J Clin Pharm Ther 2000; 25 (5): 333–40.PubMedCrossRef
27.
go back to reference Bramble MG, Suvakovic Z, Hungin AP. Detection of upper gastrointestinal cancer in patients taking antisecretory therapy prior to gastroscopy. Gut 2000; 46 (4): 464–7.PubMedCrossRef Bramble MG, Suvakovic Z, Hungin AP. Detection of upper gastrointestinal cancer in patients taking antisecretory therapy prior to gastroscopy. Gut 2000; 46 (4): 464–7.PubMedCrossRef
28.
go back to reference Brauner DJ, Muir JC, Sachs GA. Treating nondementia illnesses in patients with dementia. JAMA 2000; 283 (24): 3230–5.PubMedCrossRef Brauner DJ, Muir JC, Sachs GA. Treating nondementia illnesses in patients with dementia. JAMA 2000; 283 (24): 3230–5.PubMedCrossRef
29.
go back to reference Krol N, Wensing M, Haaijer-Ruskamp F, et al. Patient-directed strategy to reduce prescribing for patients with dyspepsia in general practice: a randomized trial. Aliment Pharmacol Ther 2004; 19 (8): 917–22.PubMedCrossRef Krol N, Wensing M, Haaijer-Ruskamp F, et al. Patient-directed strategy to reduce prescribing for patients with dyspepsia in general practice: a randomized trial. Aliment Pharmacol Ther 2004; 19 (8): 917–22.PubMedCrossRef
30.
go back to reference Batuwitage BT, Kingham JG, Morgan NE, et al. Inappropriate prescribing of proton pump inhibitors in primary care. Postgrad Med J 2007; 83 (975): 66–8.PubMedCrossRef Batuwitage BT, Kingham JG, Morgan NE, et al. Inappropriate prescribing of proton pump inhibitors in primary care. Postgrad Med J 2007; 83 (975): 66–8.PubMedCrossRef
31.
go back to reference van Vliet EP, Steyerberg EW, Otten HJ, et al. The effects of guideline implementation for proton pump inhibitor prescription on two pulmonary medicine wards. Aliment Pharmacol Ther 2009; 29 (2): 213–21.PubMedCrossRef van Vliet EP, Steyerberg EW, Otten HJ, et al. The effects of guideline implementation for proton pump inhibitor prescription on two pulmonary medicine wards. Aliment Pharmacol Ther 2009; 29 (2): 213–21.PubMedCrossRef
32.
go back to reference Waldum HL, Arnestad JS, Brenna E, et al. Marked increase in gastric acid secretory capacity after omeprazole treatment. Gut 1996; 39 (5): 649–53.PubMedCrossRef Waldum HL, Arnestad JS, Brenna E, et al. Marked increase in gastric acid secretory capacity after omeprazole treatment. Gut 1996; 39 (5): 649–53.PubMedCrossRef
33.
go back to reference Sanduleanu S, Stridsberg M, Jonkers D, et al. Serum gastrin and chromogranin A during medium- and long-term acid suppressive therapy: a case-control study. Aliment Pharmacol Ther 1999; 13 (2): 145–53.PubMedCrossRef Sanduleanu S, Stridsberg M, Jonkers D, et al. Serum gastrin and chromogranin A during medium- and long-term acid suppressive therapy: a case-control study. Aliment Pharmacol Ther 1999; 13 (2): 145–53.PubMedCrossRef
34.
go back to reference Farup PG, Juul-Hansen PH, Rydning A. Does short-term treatment with proton pump inhibitors cause rebound aggravation of symptoms? J Clin Gastroenterol 2001; 33 (3): 206–9.PubMedCrossRef Farup PG, Juul-Hansen PH, Rydning A. Does short-term treatment with proton pump inhibitors cause rebound aggravation of symptoms? J Clin Gastroenterol 2001; 33 (3): 206–9.PubMedCrossRef
35.
go back to reference Howden CW, Kahrilas PJ. Editorial: just how “difficult” is it to withdraw PPI treatment? Am J Gastroenterol 2010; 105 (7): 1538–40.PubMedCrossRef Howden CW, Kahrilas PJ. Editorial: just how “difficult” is it to withdraw PPI treatment? Am J Gastroenterol 2010; 105 (7): 1538–40.PubMedCrossRef
36.
go back to reference Ishihara M, Ito M. Influence of aging on gastric ulcer healing activities of cimetidine and omeprazole. Eur J Pharmacol 2002; 444 (3): 209–15.PubMedCrossRef Ishihara M, Ito M. Influence of aging on gastric ulcer healing activities of cimetidine and omeprazole. Eur J Pharmacol 2002; 444 (3): 209–15.PubMedCrossRef
37.
go back to reference Khalil T, Singh P, Fujimura M, et al. Effect of aging on gastric acid secretion, serum gastrin, and antral gastrin content in rats. Dig Dis Sci 1988; 33 (12): 1544–8.PubMedCrossRef Khalil T, Singh P, Fujimura M, et al. Effect of aging on gastric acid secretion, serum gastrin, and antral gastrin content in rats. Dig Dis Sci 1988; 33 (12): 1544–8.PubMedCrossRef
Metadata
Title
Inappropriate Prescribing of Proton Pump Inhibitors in Older Patients
Effects of an Educational Strategy
Authors
Hanifat Hamzat
Hao Sun
Joanna C. Ford
Joan MacLeod
Roy L. Soiza
Professor Arduino A. Mangoni
Publication date
01-08-2012
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 8/2012
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.1007/BF03262283

Other articles of this Issue 8/2012

Drugs & Aging 8/2012 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.